fashion -WSS

fashion

author：entertainment 2025-09-30 01:12:22 - browse：54597

Stephen Quake: "Our North Star for the next decade is understanding the mysteries of the cell." Chan Zuckerberg Initiative

SAN DIEGO — Decades ago, as a young physics Ph.D. student, Stephen Quake stumbled into the messy, dazzlingly complicated world of biology — and he’s stayed there ever since.

Quake, a professor of bioengineering and applied physics at Stanford, is a prolific academic whose discoveries have fueled the field of blood-based prenatal testing and the use of microfluidic chips, which allow scientists to quickly analyze DNA, RNA, proteins, and cells. He’s also head of science for the Chan Zuckerberg Initiative, or CZI, a company Mark Zuckerberg and Priscilla Chan founded in 2015 with the expressed intent to help “cure, prevent or manage all diseases by the end of this century.” The organization funds academic research and operates three biohubs in San Francisco, Chicago, and New York, each centered on goals such as building cells that can survey the body for signs of disease or deciphering the signals that drive inflammatory disease.

STAT sat down with Quake in front of an audience during the annual meeting of the Biotechnology Innovation Organization for a fireside chat about his pivot into the life sciences — and his second unexpected journey into the world of philanthropy.

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — plus in-depth analysis, newsletters, premium events, and networking platform access.

Already have an account? Log in

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $39/month

$30 for 3 months Get Started

Then $39/month

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： FDA approval of Sarepta Duchenne genetic therapy gives me hope
Next article： Precocious puberty in girls comes with mental health risks

hotspot

WSS

Novo Nordisk gets FDA approval to tout heart benefits of Wegovy

The Readout: Amylyx, Alumis, and Lundbeck drug updates

The drug industry has found itself all alone in Washington

Change Healthcare payments predicted restored March 15

Virtual Event: March of the Biosimilars

Change Healthcare cyberattack prompts Medicare loan program

leisure time

fashion

This article is exclusive to STAT+ subscribers

Unlock this article — plus in-depth analysis, newsletters, premium events, and networking platform access.

hotspot

Hepatitis C has a cure — but many Americans still lack access to it

In surprise move, FDA calls for advisory committee on Lilly's Alzheimer's drug

Medicare proposal to cover medical devices draws a mixed reaction

Creating egg and sperm cells from stem cells raises ethical issues

Anesthesiologist group: stop taking Ozempic before surgery

Former medical device CEO who sold dummy, plastic parts convicted of fraud

What does generative AI mean for health care? We asked experts

CVS Caremark has created a new ploy: the drug ‘rebate credit’

After affirmative action ruling, medical educators look to 'holistic review'

I was wrong about Geron's blood cancer drug. Now, is it a takeover target?

explore

Amylyx ALS drug fails large clinical trial

NEJM study link tiny plastics in blood vessels to heart problems

Novo Nordisk gets FDA approval to tout heart benefits of Wegovy

Readout Newsletter: Bluebird, CVS, Contineum

NEJM study link tiny plastics in blood vessels to heart problems

Creating egg and sperm cells from stem cells raises ethical issues

knowledge

hotspot

explore

focus